Evaluation of Intestinal Microbiome in Obese Kids
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00816296 |
Recruitment Status :
Withdrawn
(PI has left institution)
First Posted : January 1, 2009
Last Update Posted : August 24, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Obesity Non-Alcoholic Fatty Liver Disease | Other: Blood Draw Other: Stool collection Other: BodPod Measurement Other: Liver Ultrasound |
The goal of this study is to investigate and compare the composition of the intestinal microbiome in patients with obesity only to patients with obesity and Non-Alcoholic Fatty Liver Disease (NAFLD). In addition, we will investigate the relationship between alterations in the intestinal microbiome, immune activation, and the progression of NAFLD to Non-Alcoholic Steatohepatitis (NASH). We hypothesize that alterations in the intestinal microbiome are associated with increased immune activation and progression of obesity associated NAFLD. Based on this hypothesis we propose the following aims:
Aim 1. Identify and enroll pediatric cohort with obesity or obesity/NAFLD to study the role of the intestinal microbiome on the development of NAFLD.
- Enroll participants through the NEW Kids program for treatment of pediatric obesity at Children's Hospital of Wisconsin (CHW). Identify and classify participants through initial clinical evaluation, collect clinical metadata, and obtain and process blood and stool samples for analysis. Demonstrate feasibility by showing that participants can be recruited and participate in the specific study protocol.
- Follow study population through nutritional/exercise intervention, with follow up collection of clinical data, stool, and blood samples.
Aim 2. Characterize the intestinal microbiome through quantitative PCR and high throughput sequencing analysis of stool specimens in participants with obesity and obesity/NAFLD.
- Demonstrate feasibility by showing that sampling aliquots from patient fecal samples can be successfully analyzed by proposed methods and yield consistent results for duplicate samples.
- Compare sequencing results and metagenomic analysis for study groups with particular attention to bacterial composition and metabolic capacity associated with energy harvest, lipid and carbohydrate transport, enhancement of epithelial barrier integrity, and choline metabolism.
- Investigate whether intervention (nutritional/exercise) results in longitudinal alterations in the intestinal microbiome.
Aim 3. Characterize evidence of systemic inflammation by C-reactive protein (CRP), Tumor necrosis factor alpha (TNF-alpha)Transforming growth factor beta 1 (TGF-beta and LPS Binding Protein (LBP) levels, and analyze results in relationship to the intestinal microbiome and the presence of NAFLD.
- Compare levels of systemic inflammatory markers of participants with obesity vs. obesity/NAFLD
- Investigate whether intervention (nutritional/exercise) results in longitudinal alterations in systemic inflammation.
Study Type : | Observational |
Actual Enrollment : | 0 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Evaluation of the Intestinal Microbiome in Obese Children With and Without Non-Alcoholic Fatty Liver Disease |
Study Start Date : | October 2008 |
Estimated Primary Completion Date : | October 2011 |
Estimated Study Completion Date : | October 2012 |

Group/Cohort | Intervention/treatment |
---|---|
Controls
Obese (BMI>30) and normal AST and ALT. Between the ages of 5 and 18 years old.
|
Other: Blood Draw
2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry. Other: Stool collection Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry. Other: BodPod Measurement Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry. Other: Liver Ultrasound A liver ultrasound will be performed at study entry and 6 months after study entry. |
Liver Disease
Obese (BMI>30) and elevated AST and/or ALT (evidence of NAFLD). Between the ages of 5 and 18 years old.
|
Other: Blood Draw
2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry. Other: Stool collection Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry. Other: BodPod Measurement Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry. Other: Liver Ultrasound A liver ultrasound will be performed at study entry and 6 months after study entry. |
- Alterations in the intestinal microbiome are associated with increased immune activation and progression of obesity associated NAFLD. [ Time Frame: 3 years ]
- Characterize the intestinal microbiome through quantitative analysis of stool samples in participants with obesity and those with obesity and NAFLD. [ Time Frame: 3 years ]
- Characterize inflammatory markers of participants with obesity versus those obese participants that also have NAFLD. [ Time Frame: 3 years ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 5 Years to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age 5-18 Years old
- Willing to consent/undergo necessary procedures
- Obese (BMI>30)
- Speak English or Spanish
Exclusion Criteria:
- any other causes of liver disease
- any chronic illnesses or life threatening conditions

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00816296
United States, Wisconsin | |
Children's Hospital of Wisconsin | |
Milwaukee, Wisconsin, United States, 53226 |
Principal Investigator: | Vincent Biank, MD | Children's Hospital and Health System Foundation, Wisconsin |
Responsible Party: | Vincent Biank, Medical College of Wisconsin |
ClinicalTrials.gov Identifier: | NCT00816296 |
Other Study ID Numbers: |
CHW 08/159 GC 727 |
First Posted: | January 1, 2009 Key Record Dates |
Last Update Posted: | August 24, 2015 |
Last Verified: | August 2015 |
NAFLD Obesity Microbiome |
Liver Diseases Fatty Liver Non-alcoholic Fatty Liver Disease Digestive System Diseases |